🇺🇸 FDA
Patent

US 11484511

Pharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer

granted A61KA61K2236/331A61K31/12

Quick answer

US patent 11484511 (Pharmaceutical composition comprising THA as effective ingredient for treatment of prostate cancer) held by KOREA UNITED PHARM. INC. expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
KOREA UNITED PHARM. INC.
Grant date
Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61K, A61K2236/331, A61K31/12, A61K31/135, A61K36/9066